Inventiva S.A. is a clinical-stage biopharmaceutical company primarily focused on developing treatments for patients suffering from serious diseases with significant unmet needs. The company's innovative research and development efforts are concentrated on small molecules that modulate gene expression, aiming to address conditions such as non-alcoholic steatohepatitis (NASH), systemic sclerosis, and mucopolysaccharidoses (MPS).

Founded in 2012 and based in Daix, France, Inventiva leverages its proprietary technology platforms, coupled with expertise in transcription factors and epigenetics, to pioneer breakthrough therapies. Its pipeline includes several drug candidates at various stages of preclinical and clinical development, reflecting a robust commitment to innovation and patient care.

In the market, Inventiva S.A. plays a significant role within the biotechnology sector, particularly in niche areas that demand advanced therapeutic interventions. The company's collaborations with academic institutions and pharmaceutical corporations further underscore its integral role in driving forward scientific advancements and potential new treatments, thus impacting both the healthcare industry and the broader market landscape.